Abstract

A REVIEW ON DERIVATIVES OF ESCITALOPRAM

Aina Ndahafa Niingo, Mrutyunjaya Bhanja*, Naimesh Nanda, Sandip Prasad Tiwari

Faculty of Pharmacy, Kalinga University, Naya Raipur, Chhattisgarh India (492101)

ABSTRACT

Depression is a major public concern and a leading cause of disability worldwide. The World Health Organization (WHO) lists depression as the leading cause of illness in the world, with an estimated 300 million individuals affected worldwide contributing to worldwide disability. Not only is depression ubiquitous and widespread, but it also has the potential to be fatal; depression is thought to be a contributing factor in 90% of suicides. Psychiatric medications known as antidepressants are currently among the most often prescribed drugs for treating various forms of depression, among the most often prescribed medications is escitalopram. While there is disagreement among researchers regarding both their benefits and drawbacks with the exception of selective serotonin reuptake inhibitors (SSRI) escitalopram, the main issue with antidepressant use is the development of serious adverse reactions, including acts of suicide and ideas. Research has shown that escitalopram is superior to other SSRIs in treating severe depression because it acts faster (depressive symptoms subside after 1-2 weeks as opposed to 3-5 weeks) and causes fewer adverse effects. Owing to the significance of escitalopram discussed earlier a collection of 44 derivatives of escitalopram structures has been suggested by us; some of these structures likely exhibit markedly enhanced antidepressant efficacy when compared to the original drug.

Keywords: Escitalopram, Depression, Derivatives, Serotonin transporter.